Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Code: 2563.HK), today announced that the first patient has been dosed for one of its key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback